deltatrials
Completed PHASE3 NCT00050973

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Randomized Phase III Trial Comparing Targretin Capsules/Cisplatin/Vinorelbine Versus Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Eisai Inc.

Conditions Non-small Cell Lung Cancer
Interventions bexarotene
Updated 7 times since 2017 Last updated: May 13, 2013 Primary completion: Nov 30, 2004 Completion: Mar 31, 2005

This PHASE3 trial investigates Non-small Cell Lung Cancer and is currently completed. Eisai Inc. leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Inc.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia, Arlington Heights, United States, Ashkelon, Israel, Athens, Greece, Belfort, France, Bialystok, Poland, Birmingham, United States, Box Hill, Australia, Briey, France, Bristol, United Kingdom and 56 more location s